Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Gastroenterology Reports
Erschienen in: Current Gastroenterology Reports 9/2021

01.09.2021 | Inflammatory Bowel Disease (R Cohan, Section Editor)

Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease – the Evolving Landscape

verfasst von: Elyse A. Linson, Stephen B. Hanauer

Erschienen in: Current Gastroenterology Reports | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To update changes in the epidemiology of colorectal cancer in patients with ulcerative colitis and Crohn’s disease over the past decades.

Recent Findings

Since the mid twentieth century, studies have found that the incidence of colorectal cancer in patients with IBD has been greater than that of the general population, especially for patients with a family history of colorectal cancer, a diagnosis of primary sclerosing cholangitis, and/or pancolitis. While Crohn’s disease and ulcerative colitis are still associated with a risk of colorectal cancer, current treatment approaches and surveillance measures have markedly reduced the risk according to population-based cohort studies such that the risk is now more comparable to that of the general population.

Summary

It is predicted that by 2025, more than two million patients will be living with inflammatory bowel disease in the United States. As advanced treatment options become available to achieve histologic remissions and as surveillance techniques to detect neoplasia improve, guidelines for surveillance will continue to evolve.
Literatur
1.
Ananthakrishnan AN, Cagan A, Gainer VS, Cheng SC, Cai T, Szolovits P, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP. Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohn’s Colitis. 2014;8:956–63.CrossRef
2.
Atkinson AJ, Carroll WW. Sclerosing cholangitis. Association with regional enteritis. JAMA. 1964;188:183–4.PubMedCrossRef
3.
Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91(4):854–62.PubMedCrossRef
4.
Bonovas S, Fiorino G, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1179–92.PubMedCrossRef
5.
Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995;22(5):1404–8.PubMed
6.
Burisch J, Jess T, Martinato M, Lakatos PL. The burden of inflammatory disease in Europe. J Crohn’s Colitis. 2013;7(4):322–37.CrossRef
7.
•• Bye WA, Nguyen TM, Parker CE, Jairath V, East JE. Strategies for detecting colon cancer in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2017;9:CD000279. Recent Cochrane review concluding that surveillance colonoscopy allows for early detection and may reduce the development of CRC and associated mortality.PubMed
8.
Castano-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014;39(7):645–59.PubMedCrossRef
9.
Choi JK, Kim DW, Shin SY, Park EC, Kang JG. Effect of ulcerative colitis on incidence of colorectal cancer: results from the nationwide population-based cohort study (2003–2013). J Cancer. 2016;7(6):681–6.PubMedPubMedCentralCrossRef
10.
•• Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanasek T, et al. Effect of tight control management on Crohn’s disease (CALM): a multi-centre, randomized, controlled phase 3 trial. Lancet. 2018;390:2779–89. Recent trial assessing a different management strategy. A step-up, tight-control approach with endoscopic healing as a new end-point rather than a symptom-based approach.CrossRef
11.
Crohn B, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci. 1925;170(2):220–7.CrossRef
12.
Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol. 2012;18(29):3839–48.PubMedPubMedCentralCrossRef
13.
14.
15.
Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323(18):1228–33.PubMedCrossRef
16.
Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet. 1990;336(8711):357–9.PubMedCrossRef
17.
•• Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Sing S. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1450–61. Most recent AGA guidelines on UC management.PubMedCrossRef
18.
Gilat T, Fireman Z, Grossman A, Hacohen D, Kadish U, Ron E, Rozen P, Lilos P. Colorectal cancer in patients with ulcerative colitis. A population study in Central Israel. Gastroenterology. 1988;94(4):870–7.PubMedCrossRef
19.
Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133(4):1099–105. quiz 340–1PubMedCrossRef
20.
Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol. 2001;96:1558–62.PubMedCrossRef
21.
Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012;143(2):382–9.PubMedCrossRef
22.
Jensen AB, Larsen M, Gislum M, Skriver MV, Jepsen P, Norgaard B, et al. Survival after colorectal cancer in patients with ulcerative colitis: a nationwide population-based Danish study. Am J Gastroenterol. 2006;101(6):1283–7.PubMedCrossRef
23.
Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County. Denmark Aliment Pharmacol Ther. 2004;19(3):287–93.PubMedCrossRef
24.
Jess T, Loftus EV Jr, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck CD, Tremaine WJ, Melton LJ III, Munkholm P, Sandborn WJ. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County. Minn Gastroenterol. 2006;130(4):1039–46.
25.
• Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143(2):375–381 e1; quiz e13–4. Second largest population-based cohort study to date. Concluding that risk of IBD associated CRC is declining.
26.
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Publ Gr. 2015;12.
27.
• Kappelman MD, Farkas DK, Long MD, Erichsen R, Sandler RS, Sorensen HT, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12(2):265–273 e1. Largest population-based cohort study looking at risk of CRC in patients diagnosed with IBD between 1978 to 2010.
28.
Kassam Z, Belga S, Roifman I, Hirota S, Jijon H, Kaplan GG, Ghosh S, Beck P. Inflammatory bowel disease cause-specific moratlity: a primer for clinicians. Inflamm Bowel Dis. 2014;20(12):2483–92.PubMedCrossRef
29.
Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 1997;41(4):522–5.PubMedPubMedCentralCrossRef
30.
31.
Laine L, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2015;81:489.PubMedCrossRef
32.
•• Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517. Most recent ACG guidelines on CD management.PubMedCrossRef
33.
Long M, Sands B. When do you start and when do you stop screening for colon cancer in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2018;16:621–3.PubMedCrossRef
34.
Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F, for the European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders. J Crohn’s Colitis. 2017;11(6):649–70.CrossRef
35.
Manninen P, Karvonen AL, Huhtala H, Aitola P, Hyoty M, Nieminen I, et al. The risk of colorectal cancer in patients with inflammatory bowel diseases in Finland: a follow-up of 20 years. J Crohn’s Colitis. 2013;7(11):e551–7.CrossRef
36.
Marion JF, Waye JD, Israel Y, Present DH, Suprun M, Bodian C, et al. Chromoendoscopy is more effective than standard colonoscopy in detecting dysplasia during long-term surveillance of patients with colitis. Clin Gastroenterol Hepatol. 2015.
37.
Mooiweer E, Baars JE, Lutgens MW, Vleggaar F, van Oijen M, Siersema PD, et al. Disease severity does not affect the interval between IBD diagnosis and the development of CRC: results from two large, Dutch case series. J Crohn’s Colitis. 2012;6(4):435–40.CrossRef
38.
Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18(Suppl 2):1–5.PubMedCrossRef
39.
Munkholm P, Loftus EV Jr, Reinacher-Schick A, Kornbluth A, Mittmann U, Esendal B. Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates. Digestion. 2006;73(1):11–9.PubMedCrossRef
40.
Murthy SK, Kiesslich R. Evolving endoscopic strategies for detection and treatment of neoplastic lesions in inflammatory bowel disease. Gastrointest Endosc. 2013;77:351–9.PubMedCrossRef
41.
•• Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, JCY W, FKL C, JJY S, Kaplan GG. Worldwide incidence of prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–78. Most recent systematic review on incidence and prevalence of IBD.CrossRef
42.
O’Connor A, Packey CD, Akbari M, Moss AC. Mesalamine, but not sulfasalazine reduces the risk of colorectal neoplasia in patients with inflammatory bowel disease: an agent-specific systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21:2562–9.PubMedCrossRef
43.
•• Olen O, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J, Ekbom A, Sorensen HT, Ludvigsson J. Colorectal cancer in Crohn’s disease: a Scandinavian population-based cohort study. Lancet. 2020;5(S):475–84. Most recent population based cohort study evaluating incidence of CRC and CRC death in patients with Crohn’s disease.
44.
Persson PG, Karlen P, Bernell O, Leijonmarck CE, Brostrom O, Ahlbom A, et al. Crohn’s disease and cancer: a population-based cohort study. Gastroenterology. 1994;107(6):1675–9.PubMedCrossRef
45.
Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology. 1994;107:117–20.PubMedCrossRef
46.
•• Qiu X, Ma J, et al. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Oncotarget. 2017;8(1):1031–45. Most recent and largest systematic review assessing the effects of 5-ASA on the development of CRC.PubMedCrossRef
47.
Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007;65:998–1004.PubMedCrossRef
48.
•• Saffioti F, Gurusamy KS, Hawkins N, Toon CD, Tsochatzis E, Davidson BR, Thorburn D. Pharmacological interventions for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2017;3:CD011343. Largest review of RCT assessing therapies for PSC and possible implications on risk of malignancy, etc..PubMed
49.
Samadder NJ, Curtin K, Tuohy TM, et al. Increased risk of colorectal neoplasia among family members of patients with colorectal cancer; a population-based study in Utah. Gastroenterology. 2014;147:814–21.PubMedCrossRef
50.
Samadder NJ, Valentine JF, Guthery S, Sing H, Bernstein CN, Leighton JA, Wan Y, Wong J, Boucher K, Pappas L, Rowe K, Burt RW, Curtin K, Smith KR. Family history associates with increased risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(9):1807–13.PubMedCrossRef
51.
Sandborn WJ, Hanauer S, Van Assche G, Panes J, Wilson S, Petersson J, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohn’s Colitis. 2014;8:927–35.CrossRef
52.
Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015;81:1101–21.e13.PubMedCrossRef
53.
Smith MP, Loe RH. Sclerosing cholangitis; review of recent case reports and associated diseases and four new cases. Am J Surg. 1965;110:239–46.PubMedCrossRef
54.
Soderlund S, Brandt L, Lapidus A, Karlen P, Brostrom O, Lofberg R, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136(5):1561–7. quiz 818–9PubMedCrossRef
55.
Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56(1):48–54.PubMedCrossRef
56.
Subramanian V, Mannath J, Ragunath K, Hawkey CJ. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:304–12.PubMedCrossRef
57.
•• Ten Hove JR, Shah SC, Shaffer SR, Bernstein CN, Castaneda D, Palmela C, Mooiweer E, Elman J, Kumar A, Glass J, Axelrad J, Ullman TA, Colombel JF, Torres J, van Bodegraven A, Hoentjen F, Jansen JM, de Jong ME, Mahmmod N, van der Meulen-de Jong AE, Ponsioen CY, van der Woude CJ, Itzkowitz SH, Oldenburg B. Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study. Gut. 2018. Most recent multi-center retrospective cohort study assessing IBD patients with low risk features. Resulting in recommendations on the frequency of surveillance colonoscopy related to CRC risk in this specific population.
58.
59.
Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345–53.PubMedCrossRef
60.
Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K, Japanese Society for Cancer of the Colon and Rectum. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis. 2011;17(3):802–8.PubMedCrossRef
61.
Weedon DD, Shorter RG, Ilstrup DM, Huizenga KA, Taylor WF. Crohn’s disease and cancer. N Engl J Med. 1973;289(21):1099–103.PubMedCrossRef
62.
•• Wheat CL, Clark-Snustad K, Devine B, Grembowski D, Thornton TA, Ko CW. Worldwide incidence of colorectal cancer, leukemia, and lymphoma in inflammatory bowel disease: an updated systematic review and meta-analysis. Gastroenterol Res Pract. 2016;2016:1632439. Most recent systematic review and meta-analysis looking at the incidence of CRC in IBD.PubMedPubMedCentralCrossRef
63.
Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004;2(12):1088–95.PubMedCrossRef
64.
Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2005;22:783–8.PubMedCrossRef
65.
Yang D-H, Park SJ, Kim H-S, Park YS, Park D, Lee K-M, Jung S-A, Choi CH, Koo JS, Cheon JH, Yang S-K, Kim WH, Kim J, Kim H, Choi CR. High definition chromoendoscopy versus high-definition white light colonoscopy for neoplasia surveillance in ulcerative colitis: a randomized controlled trial. Am J Gastroenterol. 2019;114(10):1642–8.PubMedCrossRef
Metadaten
Titel
Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease – the Evolving Landscape
verfasst von
Elyse A. Linson
Stephen B. Hanauer
Publikationsdatum
01.09.2021
Verlag
Springer US
Erschienen in
Current Gastroenterology Reports / Ausgabe 9/2021
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-021-00816-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Parkinson-Krankheit | Nachrichten

Viel Bewegung in der Parkinsonforschung

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise